apc14 Antibody

What is an APC-conjugated CD14 antibody and what are its primary research applications?

APC-conjugated CD14 antibodies are monoclonal antibodies that target the CD14 protein, with the antibody molecule chemically linked to the fluorochrome Allophycocyanin (APC). CD14 is a crucial receptor involved in recognizing bacterial components, particularly lipopolysaccharides (LPS), and initiating inflammatory responses. The primary research application for these antibodies is flow cytometry, where they enable accurate detection and analysis of CD14-expressing cells .

The APC fluorochrome significantly enhances signal intensity during flow cytometric analysis, facilitating precise identification and characterization of CD14-positive cell populations. This makes these antibodies invaluable for investigating immune activation, pathogen recognition, and inflammatory processes in various experimental models . Researchers primarily use these antibodies to study monocytes, macrophages, and neutrophils, where CD14 is constitutively expressed on the cell surface .

How does the CD14 receptor function in the immune system and why is it important to study?

CD14 is a 53-55 kDa GPI-linked glycoprotein that serves as a multifunctional lipopolysaccharide receptor. It functions by binding LPS molecules in a reaction catalyzed by lipopolysaccharide-binding protein (LBP), an acute phase serum protein . CD14 associates with Toll-Like Receptor 4 (TLR4) to participate in signaling and cellular response to bacterial LPS, making it central to the innate immune response against gram-negative bacteria .

Beyond its membrane-bound form, CD14 is also found in serum as both a secreted and enzymatically cleaved GPI-anchored form. The soluble sCD14 can discriminate between structural differences in lipopolysaccharides and plays a role in neutralizing serum allochthonous lipopolysaccharides via reconstituted lipoprotein particles . Additionally, CD14 has been implicated in binding apoptotic cells, broadening its significance in immune function research .

What are the key technical specifications of commercially available APC-conjugated CD14 antibodies?

Available APC-conjugated CD14 antibodies vary in their technical specifications based on manufacturer and clone. For instance, the Sa14-2 clone (AGEL1865) is specifically designed for mouse samples and is available in sizes of 50, 100, or 200 tests . The Sa2-8 clone reacts with mouse CD14 and has weak antagonistic activity in NF-kappaB activation or TNF alpha production with LPS stimulation . For human samples, clones like 134620 and MEM-15 are available .

These antibodies typically have the following specifications:

• Excitation range: 633-647 nm

• Emission peak: approximately 660 nm

• Optimal laser: Red Laser

• Recommended usage: 0.5 μg per test (for Sa2-8) or 5 μL per test (for Sa14-2)

• Test definition: amount of antibody that will stain a cell sample in a final volume of 100 μL

• Compatible cell numbers: 10^5 to 10^8 cells/test (to be empirically determined)

How should researchers optimize flow cytometry protocols when using APC-conjugated CD14 antibodies?

When optimizing flow cytometry protocols for APC-conjugated CD14 antibodies, researchers should consider several critical factors. First, proper titration of the antibody is essential to determine the optimal concentration for specific experimental conditions. While manufacturers typically recommend 0.5 μg per test (Sa2-8) or 5 μL per test (Sa14-2), these values should be adjusted based on specific cell types and experimental goals .

For cell preparation, when working with peripheral blood mononuclear cells (PBMCs) or thioglycolate-elicited peritoneal exudate cells, standard isolation protocols should be followed with careful consideration of cell viability. The staining process should occur in a final volume of approximately 100 μL with cell numbers ranging from 10^5 to 10^8 per test, though optimal density should be determined empirically .

For instrument settings, researchers should configure their flow cytometers to optimal parameters for APC detection: excitation at 633-647 nm and emission collection at approximately 660 nm using appropriate bandpass filters. Proper compensation is essential when using multiple fluorochromes to prevent spectral overlap, particularly when using PE (phycoerythrin) alongside APC, as demonstrated in protocols showing CD8a PE and APC-conjugated antibodies used simultaneously .

What controls should be included when conducting experiments with APC-conjugated CD14 antibodies?

A comprehensive control strategy is essential for experiments utilizing APC-conjugated CD14 antibodies. At minimum, researchers should include:

• Isotype controls: For example, when using the Sa14-2 clone (rat IgG2a, κ), an appropriate isotype control would be APC Rat IgG2a, κ Isotype Control . For human CD14 antibodies, corresponding mouse IgG isotype controls should be used.

• Unstained controls: Essential for establishing autofluorescence baseline and setting proper voltage for flow cytometers.

• Single-color controls: Required for compensation when using multiple fluorochromes.

• Biological controls:

  • Positive control: Samples known to express CD14 (e.g., monocytes, macrophages)

  • Negative control: Samples known not to express CD14 (e.g., certain lymphocyte populations)

A validation experiment demonstrated in the literature shows human PBMCs stained with mouse IgG1 kappa Isotype Control APC compared to the actual APC-conjugated antibody, highlighting the importance of proper controls in distinguishing specific from non-specific staining .

What are the recommended preservation and storage protocols for maintaining APC-conjugated antibody functionality?

To maintain optimal functionality of APC-conjugated CD14 antibodies, specific storage and handling recommendations should be followed:

• Temperature conditions: Store at 2-8°C (refrigerated) and never freeze the conjugated antibody, as freezing can damage the fluorochrome-antibody complex .

• Light protection: APC is light-sensitive, so antibodies should be protected from light exposure during storage and handling to prevent photobleaching. This is typically emphasized with specific warnings like "Protect from light" in product documentation .

• Duration of stability: Most APC-conjugated antibodies maintain their activity for approximately 12 months from the date of receipt when stored properly at 2-8°C .

• Handling during experiments: Minimize light exposure during experimental procedures, and keep antibodies on ice when in use.

• Filtration specifications: Many commercial preparations are 0.2 μm post-manufacturing filtered to ensure sterility and remove aggregates .

• Reconstitution considerations: For lyophilized antibodies, proper reconstitution according to manufacturer guidelines is essential to maintain activity and prevent protein aggregation.

How can APC-conjugated CD14 antibodies be incorporated into multi-parameter flow cytometry panels for comprehensive immune cell profiling?

Designing effective multi-parameter flow cytometry panels incorporating APC-conjugated CD14 antibodies requires strategic consideration of several technical aspects. The APC fluorochrome's spectral properties (excitation: 633-647 nm; emission: 660 nm) make it compatible with red laser excitation, allowing it to be combined with fluorochromes excited by other lasers (blue: 488 nm, violet: 405 nm, etc.) with minimal compensation requirements .

For comprehensive immune cell profiling, researchers can pair CD14-APC with markers such as:

• Monocyte subset markers: CD16-FITC, HLA-DR-PE

• Macrophage activation markers: CD80-PE, CD86-FITC, CD206-PE-Cy7

• Toll-like receptor panel: TLR4-PE (particularly relevant given CD14's functional association with TLR4)

• General immune population markers: CD3-FITC, CD19-PE-Cy7, CD56-BV421

Published protocols demonstrate successful combinations, such as Anti-Human CD8a PE paired with APC-conjugated antibodies for analysis of human peripheral blood cells . When designing such panels, researchers should consider the brightness of APC (relatively bright) when selecting markers for rare or dim populations, potentially reserving APC for detection of proteins with lower expression levels.

What approaches can resolve data inconsistencies when CD14 expression patterns differ between flow cytometry and other detection methods?

When faced with discrepancies between CD14 expression patterns detected by flow cytometry using APC-conjugated antibodies versus other methods (immunohistochemistry, Western blotting, qPCR), researchers should implement a systematic troubleshooting approach:

• Antibody clone consideration: Different antibody clones may recognize distinct epitopes on CD14, potentially explaining discrepancies. For example, Sa14-2 and Sa2-8 clones for mouse CD14, or 134620 and MEM-15 clones for human CD14, might exhibit different binding characteristics .

• Protein conformation analysis: Flow cytometry detects native protein conformations, while Western blotting detects denatured proteins. CD14 exists in both membrane-bound (mCD14) and soluble (sCD14) forms, which might be differentially detected depending on the methodology .

• Quantification method standardization: Establish whether discrepancies stem from differences in sensitivity thresholds or detection limits between methods. Flow cytometry typically has a detection limit of approximately 500-1000 molecules per cell.

• Cross-validation protocol: Implement a consistent cross-validation protocol using multiple detection methods on the same sample preparation. For instance, use flow cytometry with different fluorochromes (beyond APC), fluorescence microscopy, and protein quantification methods on the same sample.

• Cellular localization assessment: CD14 can be expressed on cell surfaces or in soluble form. Methods that disrupt cellular structure might detect total CD14, while flow cytometry primarily detects surface expression unless permeabilization is performed .

How can researchers leverage APC-conjugated CD14 antibodies to investigate the CD14-TLR4 signaling axis in response to pathogens?

Investigating the CD14-TLR4 signaling axis using APC-conjugated CD14 antibodies requires sophisticated experimental approaches that exploit the antibodies' specificity while addressing the complex biology of this pathway. CD14 associates with TLR4 to participate in bacterial LPS signaling, making this interaction critical for innate immune responses to gram-negative bacteria .

Researchers can implement the following methods:

• Dual-staining flow cytometry: Combine CD14-APC with TLR4 antibodies conjugated to compatible fluorochromes (e.g., PE) to quantify co-expression patterns on cell subsets before and after pathogen exposure.

• Functional antagonism studies: Certain CD14 antibody clones, such as Sa2-8, exhibit weak antagonistic activity in NF-κB activation or TNF-α production upon LPS stimulation . This property can be leveraged to study the functional consequences of disrupting the CD14-TLR4 interaction in experimental systems.

• Signaling pathway analysis: After identifying CD14+ cells by flow cytometry, researchers can sort these populations and perform downstream analysis of TLR4-mediated signaling components (p38 MAPK, NF-κB, IRF3) in response to pathogen challenge.

• Co-immunoprecipitation following flow sorting: CD14+ cells identified and isolated using APC-conjugated antibodies can be lysed for co-immunoprecipitation experiments to assess physical interactions between CD14 and TLR4 under different pathogen challenge conditions.

• Live-cell imaging: Using photobleaching-resistant properties of APC, researchers can perform time-lapse studies of CD14 dynamics during pathogen recognition and subsequent signaling events when combined with appropriate TLR4 labeling.

What strategies can resolve weak or absent CD14 signals in flow cytometry experiments using APC-conjugated antibodies?

When encountering weak or absent CD14 signals in flow cytometry using APC-conjugated antibodies, researchers should systematically investigate several potential causes:

• Antibody titration reassessment: The recommended concentrations (0.5 μg or 5 μL per test) may not be optimal for all experimental systems . Perform a titration series ranging from 0.1-2.0 μg per test to determine the optimal signal-to-noise ratio.

• Sample preparation optimization:

  • Ensure cell viability exceeds 90% using viability dyes

  • Minimize time between sample collection and staining

  • Validate RBC lysis protocols do not affect CD14-expressing cells

  • Confirm proper Fc receptor blocking to prevent non-specific binding

• Instrumentation verification:

  • Ensure the cytometer's red laser is functioning optimally (633-647 nm)

  • Verify the appropriate emission filter is in place (660/20 nm bandpass)

  • Calibrate PMT voltage using appropriate controls

  • Check for potential laser misalignment

• Biological variables consideration:

  • Confirm sample contains CD14-expressing cells (monocytes, macrophages)

  • Consider that certain treatments or diseases might downregulate CD14 expression

  • Validate results using alternative CD14 antibody clones (Sa14-2 vs. Sa2-8 for mouse)

• Technical alternatives:

  • Consider signal amplification systems if CD14 expression is particularly low

  • Explore alternative fluorochromes if APC detection is consistently problematic

How can researchers address APC spectral overlap challenges in multi-parameter flow cytometry experiments?

Managing APC spectral overlap in multi-parameter flow cytometry experiments requires both careful panel design and proper compensation techniques:

• Panel design considerations:

  • APC (excitation: 633-647 nm; emission: 660 nm) has potential spectral overlap with fluorochromes like PE-Cy5, PerCP, and Alexa Fluor 647

  • Avoid combining APC with fluorochromes that have similar emission spectra on the same panel

  • If using tandem dyes like APC-Cy7, be aware that tandem degradation can lead to increased spillover into the APC channel

• Comprehensive compensation strategy:

  • Prepare single-color controls for each fluorochrome in the panel

  • Use the same cell type for compensation controls as experimental samples when possible

  • Include an unstained control to establish autofluorescence baseline

  • Perform compensation using automated algorithms but verify with manual adjustment

• Instrument-specific optimization:

  • Use appropriate bandpass filters (typically 660/20 nm for APC)

  • Ensure proper laser delay for optimal excitation

  • Consider using specialized cytometers with spectral detectors for complex panels

• Quality control measures:

  • Routinely validate compensation matrices using fluorescence minus one (FMO) controls

  • Monitor fluorochrome stability over time, especially with tandem dyes

  • Document cytometer performance with standardized beads before experimental runs

What are the latest methodological advances for studying soluble CD14 (sCD14) in conjunction with membrane-bound CD14 using APC-conjugated antibodies?

Recent methodological advances have expanded the capabilities for studying the relationship between soluble CD14 (sCD14) and membrane-bound CD14 using APC-conjugated antibodies:

• Dual detection systems: Innovative approaches combine flow cytometry for membrane-bound CD14 detection using APC-conjugated antibodies with ELISA or multiplex bead-based assays for simultaneous quantification of sCD14 in the same sample .

• Intracellular vs. surface staining protocols: Modified protocols incorporating cell permeabilization allow researchers to distinguish between surface CD14 (using non-permeabilized samples) and total CD14 (permeabilized samples) using the same APC-conjugated antibody .

• Real-time monitoring methodologies: Advanced imaging flow cytometry techniques enable visualization of CD14 shedding in response to stimuli, correlating membrane CD14 reduction with increased sCD14 in supernatants.

• Kinetic studies framework: Experimental designs now incorporate time-course analyses where CD14-expressing cells are identified using APC-conjugated antibodies, followed by sequential sampling to monitor changes in membrane CD14 and corresponding sCD14 release.

• Advanced bioinformatic integration: Computational approaches now correlate flow cytometry data on CD14+ cell populations (identified using APC-conjugated antibodies) with proteomic or metabolomic data on sCD14 levels and functional outcomes.

How might APC-conjugated CD14 antibodies be adapted for imaging flow cytometry and high-dimensional cytometry applications?

APC-conjugated CD14 antibodies can be adapted for advanced cytometry applications through several emerging technical approaches:

• Imaging flow cytometry integration: The strong signal intensity of APC-conjugated CD14 antibodies makes them ideal for imaging flow cytometry, where researchers can simultaneously quantify CD14 expression and visualize its cellular localization . This approach can be enhanced by:

  • Optimizing camera exposure settings for APC detection

  • Implementing mask features to distinguish membrane versus cytoplasmic CD14 localization

  • Combining with nuclear dyes and other markers for detailed morphological analysis

• High-dimensional cytometry adaptation:

  • Mass cytometry (CyTOF) analogues: Although APC itself cannot be used in mass cytometry, corresponding metal-conjugated CD14 antibodies using the same clones (Sa14-2, Sa2-8) can be incorporated into high-parameter panels

  • Spectral cytometry implementation: The distinct spectral signature of APC makes it valuable for spectral cytometry, where complete emission profiles are collected rather than specific bandwidths

• Computational analysis enhancement:

  • Dimensionality reduction techniques like UMAP or t-SNE can be applied to high-parameter datasets incorporating CD14-APC data

  • Trajectory analysis methods can track CD14+ cell populations through differentiation or activation states

  • Machine learning algorithms can identify novel CD14+ cell subsets based on combined marker expression patterns

What novel insights might be gained by studying CD14 expression dynamics in single-cell RNA-seq data correlated with protein expression using APC-conjugated antibodies?

Integrating APC-conjugated CD14 antibody flow cytometry data with single-cell RNA-seq creates powerful opportunities for multi-omic insights:

• Transcript-protein correlation analysis: By sorting CD14+ cells identified using APC-conjugated antibodies prior to single-cell RNA-seq, researchers can directly correlate CD14 protein levels with corresponding mRNA expression, revealing potential post-transcriptional regulatory mechanisms .

• Heterogeneity exploration within CD14+ populations:

  • Identifying transcriptionally distinct subpopulations within phenotypically similar CD14+ cells

  • Discovering novel marker genes that correlate with different levels of CD14 protein expression

  • Mapping developmental trajectories of CD14-expressing cells during differentiation or activation

• Regulatory network reconstruction:

  • Inferring transcription factors governing CD14 expression by correlating TF activity with protein levels

  • Identifying co-regulated gene modules associated with varying CD14 expression

  • Discovering feedback mechanisms between CD14 signaling and transcriptional responses

• Disease-specific signature identification:

  • Characterizing how pathological conditions alter the relationship between CD14 transcript and protein levels

  • Identifying disease-specific CD14+ cell states that may serve as biomarkers or therapeutic targets

  • Comparing tissue-resident versus circulating CD14+ cells at both protein and transcriptional levels

How might APC-conjugated CD14 antibodies contribute to understanding the role of CD14 in diseases beyond traditional infectious disease models?

APC-conjugated CD14 antibodies are expanding our understanding of CD14's role in various disease contexts through several innovative research approaches:

• Neurodegenerative disease investigations: Flow cytometric analysis using CD14-APC antibodies is revealing the importance of CD14-expressing microglia and infiltrating monocytes in conditions like Alzheimer's disease, multiple sclerosis, and Parkinson's disease .

• Cancer immunology applications:

  • Quantifying tumor-associated macrophage (TAM) populations using CD14-APC in conjunction with other markers

  • Studying how CD14+ myeloid-derived suppressor cells modulate anti-tumor immune responses

  • Investigating CD14 as a potential target for reprogramming the tumor microenvironment

• Metabolic disorder research:

  • Characterizing CD14+ cell dynamics in adipose tissue inflammation in obesity

  • Studying how CD14-TLR4 signaling contributes to insulin resistance

  • Exploring CD14's role in non-alcoholic steatohepatitis (NASH) progression

• Autoimmune disease studies:

  • Phenotyping CD14+ monocyte subsets in rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease

  • Investigating CD14's contribution to loss of tolerance and autoantibody production

  • Exploring CD14 as a biomarker for disease activity or treatment response

• Cardiovascular disease mechanisms:

  • Analyzing CD14+ monocyte involvement in atherosclerotic plaque formation

  • Studying CD14's role in sterile inflammation following myocardial infarction

  • Investigating CD14 as a potential therapeutic target to reduce cardiovascular inflammation